Roche Pharmaceutical Development and Sales Overview
Roche
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
Phase/study
# of patients
Locally advanced esophageal cancer (EC)
Phase III
SKYSCRAPER-07
1L esophageal cancer (EC)
Phase III
SKYSCRAPER-08
1L recurrent/metastatic PD-L1 positive
squamous cell head and neck carcinoma
(SCCHN)
Phase II
SKYSCRAPER-09
N=120
Design
"
Primary endpoint
Status
CT Identifier
N=750
N=500
■
ARM A: Tiragolumab plus Tecentriq
☐
☐
ARM B: Tecentriq plus placebo
ARM A: Tiragolumab plus Tecentriq plus
cisplatin and paclitaxel
ARM C: Placebo plus placebo
Progression-free survival (A vs C)
Overall survival (A vs C, hierarchical, B vs C
hierarchical)
FPI Q3 2020
NCT04543617
NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1
■ ARM B: Placebo plus placebo plus cisplatin
and paclitaxel
"
ARM A: Tiragolumab plus Tecentriq
ARM B: Tecentriq plus placebo
Overall survival and progression-free survival
Objective response rate
FPI Q4 2020
Recruitment completed Q4 2021
NCT04540211
FPI Q1 2021
Recruitment completed Q2 2022
NCT04665843
107
OncologyView entire presentation